Browsing by Author "Elimian, Kelly Osezele"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Assessing the capacity of symptom scores to predict COVID-19 positivity in Nigeria: A national derivation and validation cohort study(BMJ Publishing Group, 2021) Elimian, Kelly Osezele; Aderinola, Olaolu; Igumbor, Ehimarios This study aimed to develop and validate a symptom prediction tool for COVID-19 test positivity in Nigeria.A cohort of 43 221 individuals within the national COVID-19 surveillance dataset from 27 February to 27 August 2020. Complete dataset was randomly split into two equal halves: derivation and validation datasets. Using the derivation dataset (n=21 477), backward multivariable logistic regression approach was used to identify symptoms positively associated with COVID-19 positivity (by real-time PCR) in children (≤17 years), adults (18–64 years) and elderly (≥65 years) patients separately.Item Covid-19 vaccine effectiveness studies in Nigeria: Quo vadis?(International Society of Global Health, 2022) Akande, Oluwatosin Wuraola; Igumbor, Ehimario Uche; Elimian, Kelly OsezeleThe “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set [1].Item Descriptive epidemiology of coronavirus disease 2019 in Nigeria, 27 February-6 June, 2020(Cambridge University Press, 2020) Igumbor, Ehimario; Elimian, Kelly Osezele; Ochu, Chinwe LuciaThe objective of this study was to describe the epidemiology of COVID-19 in Nigeria with a view of generating evidence to enhance planning and response strategies. A national surveillance dataset between 27 February and 6 June, 2020 was retrospectively analysed, with confirmatory testing for COVID-19 done by real-time polymerase chain reaction (RT-PCR). The primary outcomes were cumulative incidence (CI) and case fatality (CF). A total of 40926 persons (67% of total 60839) had complete records of RT-PCR test across 35 States and the Federal Capital Territory, 12289 (30.0%) of whom were confirmed COVID-19 cases. Of those confirmed cases, 3467 (28.2%) had complete records of clinical outcome (alive or dead), 342 (9.9%) of which died. The overall CI and CF were 5.6 per 100000 population and 2.8%, respectively.Item Nigeria's public health response to the COVID-19 pandemic: January to May 2020(Edinburgh University Global Health Society, 2020) Dan-Nwafor, Chioma Cindy; Ochu, Chinwe Lucia; Elimian, Kelly OsezeleThe novel coronavirus disease 2019, COVID-19, which is caused by severe acute respiratory syndrome virus 2 (SARS-CoV-2) [1] was first reported in December 2019 by Chinese Health Authorities following an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province [2,3]. SARS-CoV-2 is likely of zoonotic origin, similar to SARS and Middle East Respiratory Syndrome (MERS), and transmitted between humans through respiratory droplets and fomites. Since its emergence, it has rapidly spread globally [4].